Shanghai INT Medical Instruments Co., Ltd. (INT Medical) announced that the Stock Exchange of Hong Kong granted listing approval on 13 May 2026 for the conversion and listing of 71.79 million domestic shares into H shares. The conversion involves 12 existing shareholders and represents 33.99% of INT Medical’s issued share capital.

Post-conversion, the company’s share structure will consist entirely of H shares. The total share count remains unchanged at 211.20 million, but the proportion of H shares will rise from 66.01% to 100.00%, while domestic shares will fall to zero.

Key converting shareholders and resulting stakes in the enlarged H-share register: • Dr. Liang Dongke: 12.04 million shares, 5.70% • Ningbo Huaige Taiyi Equity Investment Partnership (controlled by Mr. Wang Kai): 9.84 million shares, 4.66% • Mr. Lin Sen: 7.14 million shares, 3.38% • Mr. Wang Ruiqin: 7.14 million shares, 3.38% • Mr. Chen Xing: 7.07 million shares, 3.35% • Mr. Huang Chubin: 7.07 million shares, 3.35% • Ningbo Tongchuang Suwei Investment Partnership: 6.00 million shares, 2.84% • Mr. Wang Kai (individual holding): 5.57 million shares, 2.64% • Four partnerships controlled by Dr. Liang Dongke—Ningbo Jiaying, Ningbo INT, INT Chuangqi and INT Chuangyuan—collectively convert 9.90 million shares, adding a combined 4.70% to the free-float.

INT Medical stated it will complete the requisite share conversion and trading procedures in accordance with Hong Kong Listing Rules and will provide further updates as necessary. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.